Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis. OBJECTIVES: This study aimed to assess the efficacy and safety of bimekizumab in treating patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuqian, Li, Sheng, Bai, Juan, Cai, Xiaoxuan, Tang, Shunli, Lin, Peiyi, Sun, Qingmiao, Qiao, Jianjun, Fang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084576/
https://www.ncbi.nlm.nih.gov/pubmed/37051072
http://dx.doi.org/10.1177/20406223231163110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084576/
https://www.ncbi.nlm.nih.gov/pubmed/37051072
http://dx.doi.org/10.1177/20406223231163110

Ejemplares similares